Molecular Carcinogenesis Group, Department of Histology and Embryology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Bioessays. 2022 Jun;44(6):e2100234. doi: 10.1002/bies.202100234. Epub 2022 Mar 30.
Until recently, cardiotoxicity in the setting of a malignant disease was attributed solely to the detrimental effects of chemo- and/or radio-therapy to the heart. On this account, the focus was on the evaluation of well-established cardiac biomarkers for the early detection of myocardial damage. Currently, this view has been revised. Cardiotoxicity is not restricted to a single organ but instead affects the endothelium as a whole. Indeed, it has come into light that not only cancer therapy but also malignant cells per se can impair the cardiovascular system, through a paracrine and endocrine mode of action. Even more intriguingly, a clear interplay between molecular pathways involved in cancer and cardiovascular disease has become prevalent, suggesting a common nominator that governs the pathophysiology of these two entities. Taken together, our strategy in the quest of novel biomarkers in the emerging field of cardio-oncology should be critically reshaped.
直到最近，恶性疾病背景下的心毒性仍被认为完全是由化疗和/或放疗对心脏的有害作用引起的。因此，重点是评估成熟的心脏生物标志物，以早期发现心肌损伤。目前，这种观点已经被修正。心毒性不仅局限于单一器官，而是会影响整个血管内皮。事实上，人们已经发现，不仅是癌症治疗，而且恶性细胞本身也可以通过旁分泌和内分泌作用方式损害心血管系统。更有趣的是，癌症和心血管疾病相关分子途径之间的明确相互作用已经变得普遍存在，这表明存在一个共同的决定因素，控制着这两种疾病的病理生理学。综上所述，我们在新兴的肿瘤心脏病学领域寻找新的生物标志物的策略应该受到批判性的重新审视。
